



**HEPATOPROTECTIVE EFFECTS OF L-ORNITHINE-
LASPARTATE DURING THIAZOLIDINEDIONE
TREATMENT OF DIABETIC MALE
ALBINO RATS**

A Thesis Presented to the
Faculty of the Biological Sciences Department
College of Science
De La Salle University - Dasmariñas
Dasmariñas, Cavite

In Partial Fulfilment of the Requirements
for the Degree of Bachelor of Science Major in Human Biology

RUBY MAY Z. BELTRAN

JOAN MARIE D. TAYCO

March 2011



ABSTRACT

L-Ornithine-L-Aspartate (a hepatoprotective drug) was not able to exert its hepatoprotective effects to prevent the negative effects of Thiazolidinedione (anti-diabetic drug). The study was conducted to determine the effects of L-Ornithine-L-Aspartate in Thiazolidine-induced hepatotoxicity. Diabetes was induced to the sixty (60) male albino rats. After being diabetic, different levels L-Ornithine-L-Aspartate was administered followed by Thiazolidinedione. To check the liver damage, bilirubin and urobilinogen were measured through urinalysis. Different dosage levels of the hepatoprotective drug used did not have any effect in liver damage. The levels of urobilinogen had a significant difference in the treatment groups.





TABLE OF CONTENTS

Title Page	1
Approval Sheet	2
Acknowledgements	3
Abstract	4
Table of Contents	5
List of Tables	7
List of Figures	8
CHAPTER 1 INTRODUCTION	9
1.1 Background of the Study	9
1.2 Conceptual Framework	11
1.3 Statement of the Problem	11
1.4 Scope and Limitations	12
1.5 Significance of the Study	13
1.6 Definition of Terms	13
CHAPTER 2 LITERATURE REVIEW	15
2.1 Conceptual Literature	15
2.2 Related Studies	28
CHAPTER 3 METHODOLOGY	31
3.1 Research Design	31
3.2 Research Setting	31




3.3 Research Procedure	32
3.4 Data Gathering and Statistical Analysis	35
CHAPTER 4 RESULTS AND DISCUSSIONS	36
4.1 Results	36
4.2 Discussions	39
CHAPTER 5 CONCLUSIONS AND RECOMMENDATIONS	43
5.1 Conclusions	43
5.2 Recommendations	43
Cited References	45
Appendices	51
A. Standard Procedures	52
B. Raw Data	56
C. Photodocumentation	61
Curriculum Vitae	66



LIST OF TABLES

TABLE	PAGE
4.1 Presence or Absence of Bilirubin in Each Treatment Group	36
4.2 Normal and Above Normal Urobilinogen Levels in the Urine of Each Treatment Group	38





LIST OF FIGURES

FIGURE	PAGE
4.1 Comparative Graph of Present and Absent Bilirubin in Each Treatment Group	37
4.2 Comparative Graph of Normal and Above Normal Values of Urobilinogen within Treatment Groups	38

